Principal component analysis of dynamic contrast enhanced mri in human prostate cancer

Investigative Radiology

Volumn 45, Issue 4, 2010, Pages 174-181

  Eyal, Erez ^a   Bloch, B Nicolas ^b,c   Rofsky, Neil M ^b   Furman Haran, Edna ^a   Genega, Elizabeth M ^b   Lenkinski, Robert E ^b   Degani, Hadassa ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

3TP method; Dynamic contrast enhancement; MRI; Principal component analysis; Prostate cancer

Indexed keywords

GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DYNAMICS; EVALUATION; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; KINETICS; MALE; NOISE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARAMETER; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; ROTATION; SENSITIVITY AND SPECIFICITY; TIME;

EID: 77949847350     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181d0a02f     Document Type: Article

References (41)

1. Kety SS. Measurement of local contribution within the brain by means of inert, diffusible tracers; examination of the theory, assumptions and possible sources of error. Acta Neurol Scand Suppl. 1965;14:20-23.
2. Eyal E, Degani H. Model-based and model-free parametric analysis of breast dynamic-contrast-enhanced MRI. NMR Biomed. 2009;22:40-53.
3. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449-458.
4. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol. 2000;55:99-109.
5. Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol. 2005;2:596-607.
6. Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology. 1989;170:681-686.
7. Bloch BN, Helbich T, Heinz-Peer G. [Prostatic carcinoma: current status of diagnostic imaging]. Wien Med Wochenschr Suppl. 2002:89-91.
8. Noworolski SM, Henry RG, Vigneron DB, et al. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med. 2005;53:249-255.
9. Kiessling F, Lichy M, Grobholz R, et al. Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI. Eur Radiol. 2004;14:1793-1801.
10. van Dorsten FA, van der Graaf M, Engelbrecht MR, et al. Combined quantitative dynamic contrast-enhanced MR imaging and (1)H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging. 2004;20: 279-287.
11. Kiessling F, Lichy M, Grobholz R, et al. [Detection of prostate carcinomas with T1-weighted dynamic contrast-enhanced MRI. Value of two-compartment model]. Radiologe. 2003;43:474-480.
12. Rouviere O, Raudrant A, Ecochard R, et al. Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol. 2003;13:931-942.
13. Buckley DL, Roberts C, Parker GJ, et al. Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging\initial experience. Radiology. 2004;233:709-715.
14. Huisman HJ, Engelbrecht MR, Barentsz JO. Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate. JMagn Reson Imaging. 2001;13:607-614.
15. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 tesla. Invest Radiol. 2009; 44:572-576.
16. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10: 223-232.
17. Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue. Invest Radiol. 2009;44:577-584.
18. Zelhof B, Lowry M, Rodrigues G, et al. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int. 2009;104: 621-627.
19. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging\initial results. Radiology. 2007;245:176-185.
20. Futterer JJ, Engelbrecht MR, Huisman HJ, et al. Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology. 2005;237: 541-549.
21. Jolliffe IT. Principal Component Analysis. New York, NY: Springer-Verlag; 1989.
22. Pedersen F, Bergstrom M, Bengtsson E, et al. Principal component analysis of dynamic positron emission tomography images. Eur J Nucl Med. 1994; 21:1285-1292.
23. Razifar P, Axelsson J, Schneider H, et al. A new application of prenormalized principal component analysis for improvement of image quality and clinical diagnosis in human brain PET studies\clinical brain studies using [11CJ-GR205171, [11C]-L-deuterium-deprenyl, [11C]-5-Hydroxy-L-Tryptophan, [11CJ-L-DOPA and Pittsburgh compound-B. Neuroimage. 2006;33:588-598.
24. Cootes T, Hill A, Taylor C, et al. The use of active shape models for locating structures in medical images. Image Vis Comput. 1994;12:355-365.
25. Hagberg G. From magnetic resonance spectroscopy to classification of tumors. A review of pattern recognition methods. NMR Biomed. 1998;11: 148-156.
26. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111: 209-219.
27. Twellmann T, Saalbach A, Gerstung O, et al. Image fusion for dynamic contrast enhanced magnetic resonance imaging. Biomed Eng Online. 2004; 3:35.
28. Khazen W, M'Bika JP, Tomkiewicz C, et al. Expression of macrophage-selective markers in human and rodent adipocytes. FEBS Lett. 2005;579: 5631-5634.
29. Eyal E, Bloch B, Furman-Haran E, et al. Pattern and model based analysis of dynamic contrast enhanced prostate MRI data. Proc Intl Soc Mag Reson Med. 2007;15:523.
30. Eyal E, Furman-Haran E, Badikhi D, et al. Combination of model-free and model-based analysis of dynamic contrast enhanced MRI for breast cancer diagnosis. In: Proceedings SPIE, Medical Imaging; 2008; San Diego, CA.
31. Bloch B, Eyal E, Rofsky N. Computer-aided diagnosis of prostate cancer: clinical utility of integrating model-free and kinetic-based analysis of high spatial resolution dynamic contrast enhanced 3 tesla MRI. In: Proceedings of the International Society for Magnetic Resonance in Medicine; 2008; Toronto, Canada.
32. Eyal E, Badikhi D, Furman-Haran E, et al. Principal component analysis of breast DCE-MRI adjusted with a model-based method. J Magn Reson Imaging. 2009;30:989-998.
33. Degani H, Gusis V, Weinstein D, et al. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med. 1997;3:780-782.
34. Furman-Haran E, Grobgeld D, Kelcz F, et al. Critical role of spatial resolution in dynamic contrast-enhanced breast MRI. J Magn Reson Imaging. 2001;13: 862-867.
35. Kelcz F, Furman-Haran E, Grobgeld D, et al. Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. Am J Roentgenol. 2002;179:1485-1492.
36. Pesce LL, Metz CE. Reliable and computationally efficient maximum-likelihood estimation of "proper" binormal ROC curves. Acad Radiol. 2007; 14:814-829.
37. Franiel T, Ludemann L, Rudolph B, et al. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. Invest Radiol. 2008;43:481-487.
38. Ren J, Huan Y, Wang H, et al. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol. 2008;63:153-159.
39. Preziosi P, Orlacchio A, Di Giambattista G, et al. Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol. 2003;13:925-930.
40. Ogura K, Maekawa S, Okubo K, et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology. 2001;57:721-726.
41. Turnbull LW, Buckley DL, Turnbull LS, et al. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging. 1999;9:311-316.